Publications by authors named "Koji Niibe"
Article Synopsis
- Ivabradine is a new treatment for heart rate reduction in patients with reduced ejection fraction heart failure, and this study evaluates its cost-effectiveness in Japan.
- A Markov model was used to compare ivabradine plus standard therapy against standard therapy alone, focusing on Quality-Adjusted Life Years (QALY) for patients with resting heart rates ≥ 75 bpm and ≥ 70 bpm.
- The study found that ivabradine is likely cost-effective, with an incremental cost-effectiveness ratio of around JPY 2.46 million to JPY 2.56 million per QALY, making it a viable option for patients with chronic heart failure in Japan.
Background: Cancer cachexia is a multifactorial syndrome leading to progressive functional impairment. How cachexia affects the treatment course of chemotherapy in patients with pancreatic cancer has not been well understood.
Methods: This is an exploratory, retrospective, observational cohort study using the Japanese medical claims database from Medical Data Vision Co.